16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.; 10.06.2021 · olemedia/e+ via getty images. Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.;
10.06.2021 · olemedia/e+ via getty images. Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.;
16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.;
Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 10.06.2021 · olemedia/e+ via getty images. 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.;
Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.; 10.06.2021 · olemedia/e+ via getty images.
Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.; 10.06.2021 · olemedia/e+ via getty images.
10.06.2021 · olemedia/e+ via getty images.
Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 10.06.2021 · olemedia/e+ via getty images. 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.;
10.06.2021 · olemedia/e+ via getty images. Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.;
10.06.2021 · olemedia/e+ via getty images. Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.;
Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.;
10.06.2021 · olemedia/e+ via getty images. Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.; 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.;
Nasdaq 115M Ipo Seekingalpha - How To Invest In Hydrogen Part 2 Top Picks Seeking Alpha : Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.;. 10.06.2021 · olemedia/e+ via getty images. 16.06.2021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $37.75/share, for expected gross proceeds of ~$115m.; Online antiques platform 1stdibs.com (nasdaq:dibs) raised $115m after pricing its ipo at $20 share and valuing the company at about $750m.;
16062021 · protagonist therapeutics (nasdaq:ptgx) has priced its public offering of 3,046,358 common shares at $3775/share, for expected gross proceeds of ~$115m; nasdaq. 10.06.2021 · olemedia/e+ via getty images.